Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Investor Presentation (June 2022)
19 slides from Aspira Women's Health's investor presentation, Jun 7, 2022

Slide 1: Transforming the State of Women's Gynecological Health... Starting with Ovarian Cancer
Transforming the State of Women’s Gynecological Health... Starting with Ovarian Cancer Corporate Presentation | June 2022 Nicole Sandford, President and CEO Bob Beechey, Chief Financial Officer

Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

Slide 3: Investment Highlights
Investment Highlights Commercial : : : Revenue-generating test for multi-modal ovarian cancer risk assessment FDA-cleared Technologies ar Focused fiaeustiasli i i i Compelling pipeline of gynecological diagnostic tools Intellectual i Strong IP and technology protection Managed Care Approximately 200

Slide 4: Recent Developments
Recent Developments Aspira will collaborate with BioReference Laboratories, Inc., an OPKO Health company and the largest full-service specialty laboratory in the United States, to offer OVA1Plus, which includes Aspira’s FDA-cleared Ova1 and Overa ovarian cancer risk assessments. BioReference + With

Slide 5: Starting with Ovarian Cancer...
Starting with Ovarian Cancer... Most Ovarian Cancer Detected at Late Stage — When It’s Most Deadly Presentation Stage | Stage Il Stage Ill Stage IV Stage Local Pelvic Regional nodes Distant spread Incidence a “ pm Five Year 2% % 29% 24% Survival Rate? ° e ° Ovarian Cancer Diagnosed in the Late Stage

Slide 6: Current Standard of Care for Assessing Cancer Treatment
Current Standard of Care for Assessing Cancer Treatment Clinical Assessment Physical exam and ultrasound CA 125 (off-label) ROMA™ (alternative) Limitations: Subjective results and Limitations: Low sensitivity and reliance on physician high false negatives, especially in and technician experience pre

Slide 7: A Better Blood Risk Assessment
A Better Blood Risk Assessment Cva J OVA products demonstrate better performance in early-stage risk detection OVA risk assessment products 31% substantially improve the effectiveness of clinical assessment in stratifying the risk of Stage 1 and Stage 2 malignancy for women with pelvic masses planne

Slide 8: Significant Market Opportunity
Significant Market Opportunity OVA products address the unmet need and represent a significant growth opportunity for Aspira. OVA1Plus Pelvic Mass — Potential Revenue Women Planned For Surgery $100M-140M TAM=300-400K OVAWatch Pelvic Mass (one time and serial mass monitoring) TAM=1.2-1.5M Potential R

Slide 9: Commercial Strategy
Commercial Strategy The expansion and commercialization of our OVA products is a top priority for 2022 Commercial Strategy Focus Sales Force Optimization Targeting gynecologic specialists, Adoption and Coverage 26 full-time women’s health specialized sales groups and professionals healthcare systems

Slide 10: Adoption and Coverage
Adoption and Coverage OVA Adoption Since Introduction of Second-Generation Test OVA volumes have increased o' time even during the Covid pandemic Professional Society Suppo: 5000 _ #ACOG © £ 2 4000 $ 8 © 3500 Boley 6F Gypeolgic Oncaigs $ fe} 3000 SpecialtyHealth, 2500 BORG evicore * 2000 healtheare’

Slide 11: OVA Adoption by Physicians Continues to Improve
OVA Adoption by Physicians Continues to Improve Total Ordering Physicians 3500 3000 66 OVAtplus™ has made a big difference in my practice because it has added more aop8 certainty to decision-making and given us more confidence in treating patients. 99 2090! ObGyn 66 | ask my referring OBGYN’s 1500 a

Slide 12: Market Access
Market Access Our goal is to make OVA products available to all women 168 Million Commercial lives covered HCSC {Cigna a ® A&E <HIIGHMARK. —WAwellCare TRICARE eth Pans Commercial coverage also includes Medicare Advantage plans sponsored by additional commercial payers 66% of all commercial lives cov

Slide 13: OVAWatch
CvawatTcH OVAWatch is our third generation OVA product. It is a non-invasive Lab Developed Test (LDT) to be used in conjunction with clinical assessment to determine the risk of ovarian cancer for patients with an adnexal mass. « Expands patient population from OVA1Plus which is FDA Launch in two st

Slide 14: OVAWatch Launch Plan
CvawaT,cH Launch Plan Product Expansion Initial Commercial Launch 2H 2022 Targeted for second half 2022; revenue in 2023 Pricing/Reimbursement In process Cross-walk from existing reimbursement arrangements for OVA1Plus Clinical Validation In process Analysis of interim data from prospective real-wor

Slide 15: Endometriosis is an Unmet Need — and Market Opportunity
|e | Endometriosis is an Unmet Need — and Market Opportunity Product Expansion Health Cost 6-7 mition women affected in the Burden tener For women diagnosed with Endometriosis in the U.S. is similar to * EndoCheck™ is our in-development Average to diagnose test for endometriosis targeted for the cos

Slide 16: Aspira Synergy: Phases of the Client Relationship Lifecycle
Aspira Synergy: Phases of the Client Relationship Lifecycle Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Agreement Implementation Launch Adoption/Scale Optimization Super Group A s Salesand Adoption: = guneent + Revenue Drive awareness and Regional physician adoption LabB Regional o LabA = Client Validat

Slide 17: Financial Performance Snapshot
Financial Performance Snapshot Qi vs. Last Year OVA Product Volume INCREASED 28% 4,819 units in O2FY22 vs. 3,775 units in Q1FY21 OVA Product Revenue INCREASED 29% $1.8M in Q1FY22 vs. $1.4M in Q1FY22 Profitability GM 53.2% Total Customers INCREASED 26% 3,275 physicians in Q1FY22 vs. 2,595 physicians

Slide 18: In Conclusion ...
In Conclusion ... Our strategy is sound, the path forward is clear. 2022 is about Accelerated Development Ova?” CvawaTcH End ocHECK Operational Excellence ¥ 18 Adoption and Volume Initial Launch

Slide 19: Contact Information
Contact Information Ashley R. Robinson LifeSci Advisors, LLC [email protected]
Source: SEC EDGAR · 8-K filed Jun 7, 2022
More decks from Aspira Women's Health Inc.
Investor Presentation (December 2025)35 slides · Dec 31, 2025
Investor Presentation (January 2025)26 slides · Jan 13, 2025
Technical Presentation (October 2024)47 slides · Oct 29, 2024
Investor Day (October 2024)42 slides · Oct 29, 2024
Investor Presentation (September 2024)30 slides · Sep 13, 2024
Fact Sheet (June 2024)2 slides · June 2024